Dr. Luis G. Paz-Ares reviewed new IMforte trial results at the 2025 ASCO Annual Meeting. Read more
Author Dr. David Spigel says these findings may pave the way for more accurate, biomarker-guided decisions for lung cancer treatment after surgery. Read more
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption. Read more
Drs. Rachael Murray and Emma O’Dowd say despite increasing evidence that cessation efforts within screening programs are effective, a lack of clear guidance means this opportunity is often missed. Read more
VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC. Read more
Dana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment. Read more
California firefighter Daiyo Ito says that while the Los Angeles County wildfires brought increased health risks for his mother, the biggest obstacle to her care and treatment was navigating her lung cancer diagnosis within a broken healthcare system. Read more
According to recent phase II data, the experimental treatment demonstrated a median overall survival of 24.5 months. Read more
The US FDA grants accelerated approval to telisotuzumab vedotin-tllv for advanced NSCLC with high c-Met overexpression. Read more